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In the past two decades, molecular biology research has 
revealed the intimate mechanisms of epidemiologically 
significant diseases, such as cancer, infections and 
immunological disorders. As the next step beyond 
seeking the mechanisms involved, scientists are now 
increasingly making it possible to regulate human bio­
logical reactions. In recent years, there have been break­
throughs in genetic engineering related to the inventory 
and methods necessary to physically construct and 
assemble biomolecular parts, such as synthetic RNA­
based regulatory systems [1]. Synthetic biology relies on 
the engineering of biological systems that perform 
human­defined functions and on the synthesis of 
complex, biologically based systems that show functions 
that do not exist in nature. Despite the possible 
advantages for clinical applications, more work remains 
to be done to elucidate the principles of biological 
design, and to overcome the scientific and technical 
challenges in designing and building more effective 
systems that are harmless to humans and therefore 
useful for clinical applications.
A recent study by Chen et al. [2] has produced a signi fi­
cant advance in solving such issues and therefore 
potentially bridging the gap between the bench and the 
bedside for synthetic RNA­based regulatory systems. The 
authors [2] developed a modular device composed of a 
sensor (an aptamer) and a gene­regulatory component (a 
hammerhead ribozyme) and tested its ability to affect the 
expression of cytokines important for the function of T­
lymphocytes in mouse and human systems.
Why is this work [2] significant? First, it represents the 
logical continuation of years of experimental work 
performed by the same group, coming from a team that 
understands the way a synthetic RNA­based regulatory 
system works and its immediate practical applications. In 
fact, in a previous study [3], also published in Proceedings 
of the National Academy of Sciences of the United States 
of America, the authors were the first to develop and set 
up universal RNA­based regulatory platforms, called 
ribozyme switches, by using engineering design princi­
ples. In the present report [2], the authors expanded the 
advantages of such biomodular platforms to a broader 
range of applications. They were able to do so by the 
reliable de novo construction of modular, portable and 
scalable control systems that can achieve flexible regu la­
tory properties, such as up­ and down­regulation of 
target expression levels and tuning of regulatory res­
ponses to fit application­specific performance requirements.
Second, the authors [2] applied the synthetic RNA 
regulatory device to a significant medical issue, the use of 
adoptive cell transfer (ACT) [4]. The ACT strategy uses 
T­cell­based cytotoxic responses to attack malignant cells 
(or any other types of abnormal cells) that escape the 
body’s natural surveillance by using T cells that have a 
natural or genetically engineered reactivity to a patient’s 
cancer cells. For this purpose, T cells have first to be 
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naturally or genetically engineered to react against a 
tumor­specific antigen, then expanded and made more 
effective in vitro, and finally adoptively transferred into a 
cancer patient. However, the clinical efficacy of ACT, so 
far, has been limited. There are many reasons for this, and 
insufficient persistence and reactivation of infused T cells 
are among the main ones. Conventional strategies for 
enhancing the persistence of transferred T cells include 
ablation of all white blood cells (myeloablative methods), 
such as total body irradiation and administration of toxic 
levels of interleukin (IL)­2. However, myeloablation is 
associated with considerable morbidity, caused by 
decreased immune response and increased risk of infec­
tion [5]. Therefore, safer and more effective thera peutic 
strategies are yet to be discovered.
Chen et al. [2] report on a synthetic RNA regulatory 
system, which marks a new era in adoptive T­cell therapy 
because of the increase in the amount and survival of 
infused T cells found with this system. Their system for 
the control of mammalian T­cell proliferation is based on 
a platform of assembled RNA devices formed by a 
modular sensor (aptamer) and a gene­regulatory 
(hammer head ribozyme) component. This device con­
verts a small­molecule input to an increased gene 
expression output, in this particular case cytokine 
production. In more detail, the authors [2] fused a 
theophylline ribozyme switch to the 3’ untranslated 
region of a tri­functional transgene (cd19-tk-t2a-il15) 
encoding IL­15 (potent survival/proliferative cytokine of 
T cells), mutant HSV­1 thymidine kinase (acting as a 
reporter and as a suicide protein in the presence of 
ganciclovir) and CD19 (a marker for fluorescence­activated 
cell sorting and immuno magnetic selection). Using this 
system, they could strictly measure (by monitoring the 
expression of CD19) and control (by modulating the 
levels of the input molecule) the biological response 
(cell proliferation/viability).
In addition to all the in vitro evidence, the authors [2] 
demonstrated that this system worked in vivo and 
effectively modulated the T­cell growth rate in mice in 
response to theophylline administration. The growth rate 
was increased to 32% in the presence of theophylline over 
a 14 day study in mice. They further investigated its 
possible clinical application by transducing primary 
human central memory T cells with this system. In vitro 
results showed that the population of live central memory 
T cells increased by 24% and that apoptotic cell popu­
lation was decreased by 54% in the theophylline­
responsive system [2].
Finally, the presented gene regulatory system [2] 
showed significant advantages over available gene regu­
la tory techniques (synthetic inducible promoters); in 
par ticular, it provides a wide range of flexibility for 
clinical settings. Firstly, the ribozyme switches can be 
easily programmed to respond to different drug 
molecules. Secondly, the system can be stringently 
controlled and finely tuned by adding additional drug­
responsive ribozyme switches (up to four), therefore 
achieving lower basal gene expression levels. Thirdly, 
this system shows tight drug­mediated regulation of 
growth over an extended time period. Taking all these 
features into consideration, it is feasible that this new 
synthetic RNA­based regulatory system could have 
straightforward clinical utility.
It is likely that combining this new modular device 
framework with upcoming advances in synthetic biology 
will strongly support the tailoring of RNA­based 
regulatory systems to diverse applications in various 
clinical and laboratory environments. Yet applying these 
RNA­based regulatory systems in clinical practice may 
still require more time. In addition, there are many other 
factors that limit the use of adoptive T­cell therapy for 
cancer. For example, the failure of adoptive immuno­
therapy against cancers lies in the absence of tumor­
specific sources of T cells [6]. If such obstacles are not 
overcome, efficacy of these systems will be significantly 
limited in clinical practice. Also, recent data support the 
combined roles of protein­coding genes and non­coding 
RNAs, such as microRNAs, in the pathogenesis of 
frequent diseases (such as cancer, immune and cardiac 
disorders) [7]. One question for the future is whether 
such devices can be adapted for the regulation of the 
functions of non­coding RNAs and microRNAs. The 
published research is good news, but it would be better 
to hold our cheers until the clinical trials are successfully 
completed, which we hope will be in the near future.
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